121,960 Abbott Laboratories $ABT Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc lessened its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 44.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,398 shares of the healthcare product maker’s stock after selling 121,960 shares during the period. Impax Asset Management Group plc’s holdings in Abbott Laboratories were worth $14,864,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. BlackRock Inc. increased its position in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp raised its stake in Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares in the last quarter. Bank of America Corp DE acquired a new position in Abbott Laboratories in the second quarter valued at about $1,603,607,000. Deutsche Bank AG raised its stake in Abbott Laboratories by 18.6% in the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after purchasing an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in Abbott Laboratories during the second quarter worth about $1,082,524,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of analyst reports. Royal Bank Of Canada reduced their price objective on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, October 22nd. JPMorgan Chase & Co. decreased their target price on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, October 22nd. Wells Fargo & Company boosted their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Argus downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. Finally, Wall Street Zen upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, October 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.32.

Check Out Our Latest Research Report on ABT

Abbott Laboratories Trading Down 2.6%

Shares of ABT opened at $104.64 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02. The firm has a market cap of $181.23 billion, a price-to-earnings ratio of 39.04, a PEG ratio of 1.88 and a beta of 0.54. The business’s fifty day moving average is $103.89 and its 200-day moving average is $101.74.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting the consensus estimate of $1.42. The business had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. Abbott Laboratories’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.30 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s payout ratio is presently 94.03%.

Insider Buying and Selling

In other news, EVP Mary Moreland sold 3,500 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the transaction, the executive vice president owned 100,791 shares of the company’s stock, valued at approximately $11,691,756. This represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.46% of the company’s stock.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Featured Articles

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.